      Document 0116
 DOCN  DRG0116
 UNIQUE IDENTIFIER        DRG-0131
 NAME OF SUBSTANCE        Insulin-Like Growth Factor I [Facts and
                          Comparisons 1995]
 REGISTRY NUMBER          67763-96-6
 RELATED REGISTRY NUMBER  61461-67-4
 STANDARD CHEMICAL NAME   Insulin-like growth factor I [USP DI 1995]
 SYNONYMS                 IGF-I [MeSH]
 SYNONYMS                 Somatomedin C [MeSH]
 SYNONYMS                 rhIGF-I [AmFAR Tx Dir 1995;7(4)]
 SYNONYMS                 Sulfation factor C [CHEMLINE]
 SYNONYMS                 Myotrophin [USP DI 1995]
 PROTOCOL ID NUMBERS      NCI 91 C-234
 PROTOCOL ID NUMBERS      NCI 93 C-21
 SECONDARY SOURCE ID      DRG
 PHARMACOLOGICAL ACTION   Insulin-like growth factor I (IGF-I) is
                          believed to be secreted by the liver and
                          circulating in the blood. It has growth
                          regulating, insulin-like, and mitogenic
                          activities. The growth factor has a major but
                          not absolute dependence on somatotropin. It
                          is believed to be mainly active in adults in
                          contrast to IGF-II which is a major fetal
                          growth factor. Cumulative nitrogen retention
                          was positive in 10 patients receiving low
                          dose (4 mcg/kg/h) and high dose (12 mg/kg/h)
                          IV infusions for 10 days. [CHEMLINE] [J Clin
                          Endocrinol Metab 1994 Feb;78(2)]
 DISEASES STUDIED/TREATED Mediates effects of human growth hormone;
                          used to treat HIV-associated wasting [AmFAR
                          Tx Dir 1995;7(4)] [J Clin Endocrinol Metab
                          1994 Feb;78(2)]
 CLASSIFICATION CODE      Immunomodulator [AmFAR Tx Dir 1995;7(4)]
 OTHER MAJOR USES         Amytrophic lateral sclerosis (ALS) [USP DI
                          1995]
 ADVERSE EFFECTS          Hypoglycemia and jaw tenderness, primarily at
                          high doses, headache, flushing and mild
                          pruritic macropapular eruptions have been
                          reported. [AmFAR Tx Dir 1995;7(4)] [J Clin
                          Endocrinol Metab 1994 Feb;78(2)]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: A polypeptide hormone
                          structurally related to insulin, identical to
                          the endogenous protein and is considered a
                          mediator of the effects of growth hormone
                          [AmFAR Tx Dir 1993;6(4)]
 SUBSTANCE DELIVERY DATA  MODE OF DELIVERY: Intravenous or subcutaneous
                          injection. [AmFAR Tx Dir 1995;7(4)] [J Clin
                          Endocrinol Metab 1994 Feb;78(2)]
 MANUFACTURERS            Genentech, Incorporated
 REFERENCES               Kooijman R, van Buul-Offers SC, Scholtens LE,
                          Schuurman HJ, Van den Brande LJ, Zegers BJ. T
                          cell development in insulin-like growth
                          factor-II transgenic mice. J Immunol. 1995
                          Jun 1;154(11):5736-45.
 REFERENCES               Lieberman SA, Butterfield GE, Harrison D,
                          Hoffman AR. Anabolic effects of recombinant
                          insulin-like growth factor-I in cachetic
                          patients with the acquired immunodeficiency
                          syndrome. J Clin Endocrinol Metab. 1994
                          Feb;78(2):404-10.
 REFERENCES               Kudsk KA, Mowatt-Larssen C, Bukar J, Fabian
                          T, Oellerich S, Dent DL, Brown E. Effect of
                          recombinant human insulin-like growth factor
                          I and early total parenteral nutrition on
                          immune depression following severe head
                          injury. Arch Surg. 1994 Jan;129(1):66-70;
                          discussion 70-1.
 REFERENCES               Bukar JG, Jackson L, Muro J, Jenks BH, Bakst
                          R, Brodsky M, Gesundheit N. Effect of a
                          combination of growth hormone (rhGH) and
                          insulin-like growth factor-I (rhIGF-I) on the
                          appetite of HIV-1+ patients (PTS) with weight
                          (WT) loss. Int Conf AIDS. 1994 Aug
                          7-12;10(2):222 (abstact no. PB0903).
 REFERENCES               Mulligan K, Grunfeld C, Hellerstein MK, Neese
                          RA, Schambelan M. Anabolic effects of
                          recombinant human growth hormone in patients
                          with wasting associated with human
                          immunodeficiency virus infection. J Clin
                          Endocrinol Metab. 1993 Oct;77(4):956-62.
 REFERENCES               Bornstein P, Mercado M, Phair J, Murphy R.
                          Human growth hormone (HGH) and insulin-like
                          growth factor-1 (IGF-1) in HIV-infected
                          patients. Int Conf AIDS. 1993 Jun
                          6-11;9(1):293 (abstract no. PO-B02-0950).
 REFERENCES               Geffner ME, Bailey RC, Bersch N, Vera JC,
                          Golde DW. Insulin-like growth factor-I
                          unresponsiveness in an Efe Pygmy. Biochem
                          Biophys Res Commun. 1993 Jun
                          30;193(3):1216-23.
 REFERENCES               Geffner ME, Bersch N, Golde DW. Insulin and
                          IGF-I stimulate normal and virally
                          transformed T-lymphocyte cell growth in
                          vitro. Brain Behav Immun. 1992
                          Dec;6(4):377-86.
 ENTRY MONTH              9112
 LAST REVISION DATE       951031
 

SOURCE: National Library of Medicine, Bethesda, MD.  Distributed by AEGIS.
